# AI Drug Repurposing System: Knowledge Graph + Large Model Helps Old Drugs Find New Uses

> Introduces an end-to-end drug repurposing system based on knowledge graphs and large language models, using CrewAI multi-agent collaboration to quickly discover new indications for existing drugs.

- 板块: [Openclaw Llm](https://www.zingnex.cn/en/forum/board/openclaw-llm)
- 发布时间: 2026-04-07T04:44:06.000Z
- 最近活动: 2026-04-07T08:03:07.271Z
- 热度: 136.7
- 关键词: 药物重定位, 知识图谱, 大语言模型, AI药物发现, CrewAI, 多智能体, 生物医学
- 页面链接: https://www.zingnex.cn/en/forum/thread/ai-45f20dc2
- Canonical: https://www.zingnex.cn/forum/thread/ai-45f20dc2
- Markdown 来源: floors_fallback

---

## Introduction: AI Drug Repurposing System—Knowledge Graph + Large Model Empowers Old Drugs for New Uses

This article introduces an end-to-end drug repurposing system based on knowledge graphs and large language models. Through CrewAI multi-agent collaboration, it quickly discovers new indications for existing drugs, aiming to address the pain points of traditional new drug development—long cycle (10-15 years) and high cost (over $2.6 billion)—and unlock the untapped therapeutic value of already marketed old drugs.

## Background of Drug Repurposing and Limitations of Traditional Methods

### Background
Developing a new drug takes an average of 10-15 years and $2.6 billion, while drug repurposing (old drugs for new uses) is an efficient alternative path. Typical cases include sildenafil (Viagra) switching from a cardiovascular drug to a treatment for erectile dysfunction, and thalidomide changing from a teratogenic drug to a treatment for multiple myeloma.

### Traditional Method Dilemmas
- **Phenotypic screening**: High cost, low efficiency, difficult to explain mechanisms
- **Target screening**: Relies on understanding of disease mechanisms; most disease targets are unknown
- **Clinical observation**: Relies on luck, cannot be carried out systematically
- **Literature mining**: Limited ability of manual processing of massive literature

Traditional methods can no longer meet the needs of the explosive growth of biomedical data.

## Core Technologies and System Architecture of AI Drug Repurposing

### Core Technologies
1. **Knowledge Graph**: Integrates multi-source data such as DrugBank and OMIM, constructs a drug-disease-gene association network, and reveals potential therapeutic paths through entity nodes and relationship edges
2. **Large Language Model**: Processes unstructured literature, extracts entity relationships, understands context, infers hypotheses, and generates verifiable scientific conclusions
3. **Multi-agent Collaboration**: Under the CrewAI framework, agents for data collection, knowledge integration, hypothesis generation, evidence evaluation, and priority ranking work collaboratively

### End-to-end System Architecture
- **Data Layer**: Integrates structured (database) and unstructured (literature) data and updates in real time
- **Knowledge Graph Construction Layer**: Entity recognition, relationship extraction, graph embedding (GNN)
- **Reasoning Layer**: Link prediction, path reasoning, large model enhancement, multi-agent collaboration
- **Evaluation Layer**: Evaluation of literature evidence, mechanism rationality, safety, and clinical value
- **Output Layer**: Candidate drug list, mechanism explanation, evidence report, visualization interface

## Practical Application Case of AI Drug Repurposing: Candidate Screening for Alzheimer's Disease

Taking Alzheimer's disease as an example, the system process is as follows:
1. **Knowledge graph query**: Obtain information such as pathogenic genes (APP/PSEN1/PSEN2), pathological features, and signaling pathways
2. **Candidate identification**: Find drugs acting on relevant pathways (e.g., anti-inflammatory drugs)
3. **Literature mining**: Retrieve studies supporting the protective effect of the drug in Alzheimer's disease models
4. **Mechanism reasoning**: The drug reduces amyloid toxicity by inhibiting neuroinflammation
5. **Safety evaluation**: Focus on side effects in elderly patients
6. **Priority ranking**: Generate candidate list and report

This process takes only a few minutes to hours, much faster than the weeks/months required by traditional methods.

## Technical Challenges and Solutions of AI Drug Repurposing

### Challenges and Responses
1. **Data Quality**: Noise/inconsistency/missing → Cleaning and standardization + entity linking + quality assessment
2. **Graph Sparsity**: Few known relationships → Large model supplements literature knowledge + GNN topological reasoning
3. **Causal Identification**: Correlation ≠ causation → Causal inference + time series data + mechanism knowledge
4. **Clinical Translation**: Laboratory results are difficult to reproduce → Multi-level verification (computational → in vitro → animal → clinical) + real-world data
5. **Interpretability**: Black-box prediction → Interpretable reasoning paths + confidence scores + human-machine collaboration

## Future Outlook and Conclusion of AI Drug Repurposing

### Future Outlook
- Larger-scale knowledge graphs: Cover more entities and relationships
- Multimodal models: Integrate text/molecule/protein/image data
- Agent collaboration upgrade: More autonomous handling of complex tasks
- Dry-wet experiment closed loop: Accelerate candidate verification
- Personalized repurposing: Based on individual patient characteristics

### Conclusion
AI technologies (knowledge graph + large model + multi-agent) provide an efficient path for drug repurposing. Although experimental verification and expert judgment are needed, it has become a powerful assistant in drug development, accelerating the transformation from "ten years to sharpen a sword" to "old drugs for new uses", and bringing hope to patients for faster access to effective treatment.